To assess long-term treatment efficacy of low dose rate brachytherapy for the treatment of localised prostate cancer.
Cause of death annotation in our prospective database was supplemented with death certificate information obtained via an internal audit of patients treated from 1999 to 2017 with low dose rate prostate brachytherapy (LDR-PB) as monotherapy or as combination with androgen deprivation therapy (ADT) and/or external beam radiotherapy (EBRT).